Understanding how immune features predict immunotherapy response in diffuse large B-cell lymphoma
Official title: Integrative approach to identify genomic features that shape the immune landscape and predict immunotherapy response in diffuse large B cell lymphoma
Funded at University of Chicago · NIH-11353865 · Data updated 2026-11-12
A study to find genomic and immune markers in diffuse large B-cell lymphoma that could help predict who benefits from immunotherapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2026 |
| Award (this year) | $367,186 |
| NIH project number | 5R01CA273241-04 |
| Project ID | NIH-11353865 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with relapsed or refractory diffuse large B-cell lymphoma who are candidates for immunotherapy.
✕Less likely to help
Patients whose lymphoma lacks the identified immune/genetic features or who are not eligible for immunotherapies may not benefit.
What this research studies
This project looks at how the immune environment inside a person’s lymphoma relates to how well they respond to treatments like checkpoint inhibitors or CAR-T therapy. Researchers will analyze gene expression data from hundreds of lymphoma samples to identify immune patterns linked to treatment response. The goal is to provide a clearer picture of which patients might benefit from specific immunotherapies and why. This work could help tailor treatments to individual patients based on their lymphoma’s immune and genetic features.
Why it matters
Potential benefit: If successful, patients could receive more personalized immunotherapy options with a higher chance of response.
How similar studies have gone: Prior studies in solid tumors show immune environment profiling can predict response; this study extends similar concepts to DLBCL.
Where this research is happening
-
University of Chicago
Chicago, United States Active
Researchers
- Principal investigator: Kline, Justin Paul — University of Chicago
- Study coordinator: Kline, Justin Paul
Related research
Other NIH-funded projects on the same topics.
-
Understanding how genes affect immune responses in lymphoma treatment
This study is looking at how the immune system interacts with diffuse large B cell lymphoma (DLBCL) to find out which genetic traits might help predict how well patients will respond to immunotherapy, so that treatments can be better tailored for those whose cancer has come back or hasn’t responded to other treatments.
-
Immunotherapy for B-cell lymphoma using NK T cells
A patient-focused immunotherapy approach using natural killer T cells engineered to target B-cell lymphoma, potentially offering off-the-shelf treatment options.
-
Immune Evasion by HLA-E in Diffuse Large B-Cell Lymphoma
A researcher is studying how a molecule called HLA-E helps a type of blood cancer (DLBCL) hide from the immune system, with findings that may lead to better treatments.
-
Cardioprotective treatment choices for DLBCL patients at risk of heart damage
Atrially, this study tests two heart-protecting drugs given during cancer treatment to see which best prevents heart problems in patients with diffuse large B-cell lymphoma who are at higher risk for heart damage.
-
Translating Genomics to Practice to Overcome Disparities in DLBCL
A patient-focused project aims to understand why diffuse large B-cell lymphoma outcomes differ among people and how genomic information can guide better care for diverse groups.
-
From pathogenesis to new targets for treating diffuse large B-cell lymphoma
A patient-focused look at how this research aims to uncover new genetic clues to guide targeted therapies for diffuse large B-cell lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.